SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

04 Nov 2023 Evaluate
The company witnessed a 20.28% growth in the revenue at Rs. 1987.55 millions for the quarter ended September 2023 as compared to Rs. 1652.50 millions during the year-ago period.The Total Profit for the quarter ended September 2023 of Rs. 202.42 millions grew from Rs.-33.22 millionsThe company reported a good operating profit of 318.81 millions compared to 236.63 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 1987.55 1652.50 20.28 3816.75 2962.38 28.84 6658.98 5569.74 19.56
Other Income 81.82 58.40 40.10 100.68 87.71 14.79 194.31 90.03 115.83
PBIDT 318.81 236.63 34.73 559.09 390.44 43.19 1030.49 662.62 55.52
Interest 37.98 92.21 -58.81 93.43 170.61 -45.24 322.26 320.12 0.67
PBDT 280.83 144.42 94.45 465.66 219.83 111.83 1100.33 342.50 221.26
Depreciation 78.41 177.64 -55.86 155.49 393.93 -60.53 547.86 870.21 -37.04
PBT 202.42 -33.22 -709.33 310.17 -174.10 -278.16 552.47 -527.71 -204.69
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 202.42 -33.22 -709.33 310.17 -174.10 -278.16 552.47 -527.71 -204.69
Equity 507.19 408.16 24.26 507.19 408.16 24.26 408.16 408.16 0.00
PBIDTM(%) 16.04 14.32 12.02 14.65 13.18 11.14 15.48 11.90 30.08

Orchid Pharma Share Price

1009.85 -24.15 (-2.34%)
18-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.00
Dr. Reddys Lab 1267.80
Cipla 1355.80
Zydus Lifesciences 1074.30
Lupin 2327.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: